Home / 2019 / April / 01

Daily Archives: April 1, 2019

Taconic Biosciences Licenses the Wild Mouse Gut Microbiome from the National Institute of Diabetes and Digestive and Kidney Diseases

RENSSELAER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces it has obtained a license to the Wild Mouse gut microbiome from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).

Investigators at the NIDDK studied wild mice gut microbiota, finding it differs dramatically from that of laboratory mice. Taconic’s germ-free mice were used in the study, which was featured in the journal Cell (https://www.cell.com/cell/fulltext/S0092-8674(17)31065-6). For research applications, the Wild Mouse gut microbiota can be banked for future use and/or maintained in a laboratory mouse breeding colony for immediate research purposes. When transferred into laboratory mice, the microbiota promote host fitness, as seen in increased resistance to viral infection and tumorigenesis models. Taconic licensed the Wild Mouse gut microbiota from NIDDK as a complement to its existing microbiome solutions portfolio, which includes germ-free mice and custom microbiota associations. The role of the microbiome in drug discovery research is to clarify the impact of varying microbiomes on the efficacy of potential therapeutics and also to potentially identify new drug targets. By having a defined microbiome standard via the NIDDK Wild Mouse gut microbiome, customers now have a basis for comparison to better understand the microbiome of their research models.

“As demonstrated in the elegant study by Rosshart et al., mammals have co-evolved with gut microbes and this has led to health promoting effects. The Wild Mouse gut microbiota model will allow researchers to identify new host-microbe relationships as well as the potential for determining new disease protection mechanisms,” commented Dr. Alexander Maue, associate director of Taconic’s microbiome products and services.

To learn more about Taconic’s microbiome solutions portfolio, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

The content of this news release is solely the responsibility of the authors and does not necessarily represent the official views or imply endorsement of the National Institutes of Health.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com

Philips introduces DreamWisp to growing portfolio of sleep solutions

April 1, 2019

  • Over-the-nose nasal cushion with the hose on top of the head to offer unprecedented comfort for CPAP mask users
  • First-of-its-kind solution for sleep apnea patients allows them to sleep in any position they want

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of DreamWisp, the first-of-its-kind over-the-nose nasal mask that allows patients with sleep apnea to sleep in any position they want. With its robust nasal cushion and top-of-the-head tube design, DreamWisp delivers a new level of comfort and freedom of movement, providing patients with the therapy option that best suits their needs.

More than 100 million people are estimated to suffer from obstructive sleep apnea (OSA) worldwide [1]. Unfortunately, many of these patients with sleep apnea have difficulty adhering to their therapy because of the discomfort associated with CPAP masks. For those who need an over-the-nose mask, the front facial tube is often cited as the main reason why patients chose to forgo sleep apnea treatment. The DreamWisp mask solves this problem by bringing the benefit of Philips DreamWear’s unique top-of-the-head tube design to users who benefit from the seal of an over-the-nose cushion, yet continue to deal with the challenges of frontal tubing. With this CPAP mask, patients now have the option to apply an over the-nose cushion to their DreamWear masks, providing an extra level of comfort and the opportunity to improve therapy adherence.

“Throughout the world, millions of people suffer from sleep apnea and many of them struggle to adhere to therapy because of mask discomfort,” said Mark D’Angelo, Sleep Business Leader for Philips. “Designed with the patient in mind, DreamWisp helps sleep apnea patients get the rest they deserve with the ability to sleep more comfortably. As we continue to expand our sleep portfolio, our focus remains on providing patients with comfortable solutions that help them improve their sleep and overall wellbeing.”

As a leader in sleep apnea mask design, Philips has been innovating for years based on provider and patient feedback. In fact, 97 % of clinicians participating in a trial said they would recommend the DreamWisp mask to another clinician [2]. In addition, DreamWisp patients and their bed partners alike said they were satisfied with the exhalation of air from the mask, commenting both on the ability of the mask to stay in place and to maintain its seal [3].

The development of DreamWisp expands on Philips’ commitment to improving the quality of life for those with sleep and respiratory conditions. The Philips DreamWisp mask is now available for purchase through Philips-authorized home medical equipment providers and online medical equipment providers.

For additional information on Philips’ solutions for sleep and respiratory care, follow @PhilipsResp on Twitter or visit www.philips.com/DreamWisp-news.

[1] The Official STOP-BANG Questionnaire. Retrieved from http://www.stopbang.ca/osa/prevalence.php.
[2] April 2018 Clinician Ease of Use trial, n=30
[3] Users study; patient preference study n=52, March/April 2018, both at 10 and 30 days

For further information, please contact:

Kathy O’Reilly
Philips Group Press Office
Tel: +1 978-659-2638
E-mail: kathy.oreilly@philips.com

Twitter: @kathyoreilly

Meredith Amoroso
Philips Sleep and Respiratory Care
Tel: +1 724-584-8991
E-mail: meredith.amoroso@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Wildflower Featured in NetworkNewsWire Publication Discussing Opportunity in the CBD Rush

NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) — via NetworkWire — Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, titled, “CBD Going Mainstream amid Flood of New Products, Celebrity Endorsements, and Emerging Consensus about Benefits,” visit: http://nnw.fm/5xAwt

Many analysts are saying that the CBD rush is just getting started. One recent estimate indicates that the CBD market alone could eclipse the entire remainder of the cannabis market combined. Wildflower can apparently read the handwriting on the wall and intends to apply the $1.882 million in proceeds from the company’s recent, oversold private placement to good use.

A reputable brand whose stated mission is to connect people to the healing power of plants via the company’s increasingly sophisticated line of CBD vaporizers, capsules, tinctures, soaps and topicals, Vancouver-based Wildflower Wellness packs its extracts with essential amino acids and beneficial terpenes.

About Wildflower Brands

Wildflower Brands is a company headquartered in Vancouver building reputable brands and quality products that incorporate the synergistic effects of plants and their extracts. For more information, visit the company’s website at www.WildflowerBrands.co

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Receive Instant SMS Alerts from NetworkNewsWire

Text “STOCKS” to 77948

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Bombardier Signs Firm Purchase Agreement for Six Q400 Turboprops

TORONTO, April 01, 2019 (GLOBE NEWSWIRE) — March 29, 2019  Bombardier Commercial Aircraft announced today that a customer, who has requested to remain unidentified at this time, has signed an order to acquire six new Q400 aircraft.

Based on the list price of the Q400 aircraft, the firm order is valued at approximately US$ 202 million.

“The Q400 aircraft offers the perfect balance of passenger comfort and operating economics while maintaining its unmatched range and speed advantage versus other turboprops,” said Fred Cromer, President, Bombardier Commercial Aircraft. “The demand for turboprop aircraft worldwide is tremendous and the Q Series aircraft are ideally positioned to meet the needs of regional airlines as they offer a unique ability to serve diverse and challenging environments. The Q400 offers the lowest seat costs amongst turboprops, with an enhanced passenger experience and a proven 99.5 per cent reliability.”

About Bombardier
With over 68,000 employees across four business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montreal, Canada, Bombardier has production and engineering sites in 28 countries across the segments of Transportation, Business Aircraft, Commercial Aircraft and Aerostructures and Engineering Services. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2018, Bombardier posted revenues of $16.2 billion US. The company is recognized on the 2019 Global 100 Most Sustainable Corporations in the World Index. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

Notes to Editors
An image of the Q400 aircraft is posted with this press release at www.bombardier.com.

For more information on the Q400 aircraft, visit http://news.commercialaircraft.bombardier.com/media-kit/

Follow @BBD_Aircraft on Twitter to receive the latest news and updates from Bombardier Commercial Aircraft.

To receive our press releases, please visit the RSS Feed section of Bombardier’s website.

Bombardier, Q400 and Q Series are trademarks of Bombardier Inc. or its subsidiaries.

For Information
Nathalie Scott
Bombardier Commercial Aircraft
+1-416-375-3030
nathalie.scott@aero.bombardier.com
www.bombardier.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/17121c8f-f6f0-4e96-b712-977d46e0b998

New CEO Leads Terumo BCT’s Ambition to Shape the Future of Blood and Cell Technologies in Healthcare

Antoinette Gawin Focuses on Terumo BCT’s Potential to Treat Disease and Play a Greater Role in Cell Therapy and Regenerative Medicine—Serving More Patients

LAKEWOOD, Colo., April 01, 2019 (GLOBE NEWSWIRE) — Antoinette Gawin is expanding Terumo BCT, a biomedical company, beyond its heritage in working with blood centers and hospitals to serve rapidly growing areas of healthcare, such as cell therapy technologies and regenerative medicine. Terumo BCT produces technologies that collect and process blood and cells used in a wide range of therapeutic areas. As President and Chief Executive Officer, Gawin will oversee the company with nearly $1 billion in revenue and 7,000 associates supporting customers in 130 countries.https://ml.globenewswire.com/Resource/Download/916aa8a7-3fa5-41d9-a167-dce1ab4cb245?size=3

“Terumo BCT has been passionately engaged in enabling access to blood and cells around the world. Our innovations automate complex processes and help researchers and clinicians unlock the healing potential of an individual’s genetic material,” Gawin said. “We must diversify our portfolio to fund continued innovation in this cost-conscious healthcare environment and remain relevant to our customers.”

Strategies include embedding the company’s products in the cell therapy manufacturing process, increasing the awareness of therapeutic apheresis as a treatment to address autoimmune diseases, building infrastructure in growth geographies and expanding beyond devices into patient data management and services. These efforts increase Terumo BCT’s ability to influence healthcare standards and reach more patients.

Gawin succeeds David Perez, who has led the company for 20 years and will continue until June 2019 on the board of directors for Terumo Corporation, parent company of Terumo BCT. Gawin is now one of three women serving the Terumo Corporation as executive officers. This progressive Tokyo-based company has been contributing to society through healthcare for nearly 100 years.

Diverse Perspectives
Gawin values all aspects of diversity and believes diversity is a foundation for patient-centered innovation. These values are reflected in her passionate commitment to patients and drive her interest in changing policy and practices to increase access to healthcare technologies. Gawin has brought experience in public policy and her perspective as a global citizen to nonprofit organizations that promote equitable access to healthcare, education and clean water.

Gawin joined Terumo BCT in 2016 in the role of executive vice president, global commercial, bringing nearly 30 years’ experience directing diverse global teams and transformational change across Baxter and GE, with global leadership roles at GE Healthcare Technologies, GE Industrial and Power Systems, GE Information Services and GE Financial Services. She holds a master’s degree in health policy from DePaul University and bachelor’s degrees in economics and English from the University of Michigan.

About Terumo BCT
Terumo BCT, a global leader in blood component, therapeutic apheresis and cell therapy technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction technologies. We believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers. www.terumobct.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/916aa8a7-3fa5-41d9-a167-dce1ab4cb245

Media Contact
Terumo BCT
Christine Romero
Corporate Communications             
+1.303.205.2599
press@terumobct.com

Nasdaq Completes Sale of BWise® to SAI Global

NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq: NDAQ) today announced the successful completion of the sale of its BWise® enterprise governance, risk and compliance software platform to SAI Global, a recognized leader of integrated risk management solutions.

As previously announced, this transaction is a result of Nasdaq’s renewed corporate strategy to maximize the company’s technology and analytics capabilities, while also investing to enhance its leading marketplaces and the capital market clients it serves. Terms of the deal were not disclosed.

Nasdaq remains dedicated to providing corporate clients with successful access to the capital markets, accompanied by strategic C-Suite and board solutions that provide investor relations intelligence and governance insights and collaboration.

About Nasdaq:

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 100 marketplaces in 50 countries. Nasdaq is home to approximately 4,000 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com.

Forward-Looking Statements:

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to the sale by Nasdaq of BWise, the benefits of the transaction and Nasdaq’s products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control. These factors include, but are not limited to factors detailed in Nasdaq’s annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Nasdaq Media Relations Contact:

Will Briganti
+1 (678) 504-6097
william.briganti@nasdaq.com

Nasdaq Investor Relations Contact:

Ed Ditmire, CFA
+1 (212) 401-8737
ed.ditmire@nasdaq.com

Cambridge Innovation Capital completes £150 million new capital raise

Cambridge Innovation Capital completes £150 million new capital raise

1 April 2019

Cambridge Innovation Capital plc (CIC), the venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem, has completed a funding round of £150 million, bringing the total amount of capital raised to date to £275 million. The financing was supported by a geographically diverse range of new institutional and strategic investors, with the University of Cambridge and Cambridge University Endowment Fund contributing the cornerstone investment. The financing is one of the largest private financing rounds in Europe this year and more than doubles the financial resources available to CIC.

The funds raised will be used to support CIC’s current portfolio of 25 companies and enable investment in new opportunities arising from both the University of Cambridge and the wider Cambridge ecosystem.

Victor Christou, CEO of CIC, commented, “The Cambridge ecosystem holds one of the richest seams of scientific knowledge and technological innovation in the world. Since our inception in 2013, CIC has invested over £125 million in IP-rich technology and life science companies among which are leaders in fields as diverse as surgical robotics, flexible electronics, microbiome science, genomic diagnosis and edge intelligence and AI decision making software.

“We are delighted by the support CIC has received from our existing shareholders and new investors in this financing round. The additional capital will enable us to fund our existing portfolio companies and invest in promising new companies in the Cambridge ecosystem. Our relationship with the University of Cambridge, including our privileged position as a preferred investor for the University, goes from strength to strength. We look forward to continuing to work with both the University and our wider network in the Cambridge area.”

Professor Stephen Toope, Vice Chancellor of the University of Cambridge, added, “CIC has grown since its launch to become a key part of the Cambridge ecosystem. It has provided support and investment to a portfolio of leading-edge businesses, each of which has the potential to substantially improve people’s lives. The University is delighted with what CIC has achieved to date and so has decided to participate in this funding round. We look forward to continuing our close relationship with the CIC team.

Portfolio progress

In the first quarter of 2019, companies in CIC’s portfolio have achieved several notable milestones, including:

  • Liquid biopsy firm Inivata achieved Medicare reimbursement coverage for its InVisionFirst-Lung test in the United States, in certain treatment decisions relating to advanced Non-Small Cell Lung Cancer. In addition, the company recently completed a £40 million Series B fundraise to enable commercialisation of InVisionFirst-Lung and to accelerate the development of the InVision platform into new indications.
  • PragmatIC, a world leading manufacturer of ultra-low-cost flexible electronics, launched the first products in its ConnectIC family and raised over £13 million of additional funds, enabling the company to increase production of its flexible integrated circuits.
  • Imagen, an award-winning Software as a Service video management platform business, raised £6.5 million in a Series B round to expand its global operations, specifically in the US and European markets.
  • GeoSpock, the extreme-scale spatial big data integration company, raised £12 million to develop key client accounts, particularly in the strategic markets of Singapore and Japan and launched its ground-breaking Spatial Big Data Platform which enables customers to reveal hidden data insights and drive game-changing business decisions.

CIC participated in all of the funding rounds referred to above.

Goldman Sachs International acted as sole and exclusive placement agent in connection with this fundraising.

This announcement is not an offer to sell securities in the United States.

Goldman Sachs International, which is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority, is acting exclusively for CIC and for no one else in relation to this fundraising and will not be responsible to anyone other than CIC for providing the protections afforded to its clients or for providing advice in relation to the financing or any other matters referred to or described in this announcement.

For more information please contact:

Cambridge Innovation Capital
Victor Christou, Chief Executive Officer
Louise Rich, Head of Investor Relations and Communications
+44 (0)1223 764875

 

Consilium Strategic Communications (City, financial PR)
Mary-Jane Elliott
Sukaina Virji
Lindsey Neville
+44 (0)20 3709 5700

CIC@consilium-comms.com
www.consilium-comms.com

Holdsworth Associates (local and trade PR)
Rachel Holdsworth
+44 (0)1954 202789
Rachel@holdsworth-associates.co.uk

About Cambridge Innovation Capital plc

Cambridge Innovation Capital (CIC) is a venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem. CIC is committed to building leading businesses from brilliant technologies. It combines a unique relationship with the University of Cambridge with deep financial and industry links to support these businesses as they seek to fulfil their potential to change the world of tomorrow.

For more information please visit www.cicplc.co.uk or follow us on Twitter at @CambsInnovation